
Diabetes is no doubt one of the most difficult health problems of the 21st century. It is a leading cause of CKD worldwide and its increasing prevalence may explain much of the increase in prevalence of kidney failure. Diabetic patients with chronic kidney disease present an additional risk for the presence of the glycemic variability due to insulin resistance. Several studies indicated that this glycemic variability seems to be an independent cardiovascular risk factor and has more deleterious effects on endothelial function compared to sustained hyperglycemia, especially due to oxidative stress activation. Glycated hemoglobin (HbA1c) is considered the gold standard for the assessment of glycemic control. In CKD patients, there are many factors which could lead to false and misleading values of HbA1c. Among the factors that lead to falsely low HbA1c values are: reduce erythrocytes lifespan, hemolysis, iron deficiency, repeated transfusions and erythropoiesis stimulating agents. Falsely high HbA1c levels are induced by hemoglobin carbamylation. Also HbA1c is not able to identify glycemic variability. Therefore it is necessary to identify methods to assess glycemic excursions in CKD patients. Commonly used antidiabetic drugs are renally excreted and have a prolonged half-life in patients with CKD, predisposing them to the risk of episodes of hypoglycemia. Furthermore, the predialysis glycemic control is also a determinant of both mortality and progression of diabetic complications for patients on continuous ambulatory peritoneal dialysis (CAPD). Continuous glucose monitoring system may represent a useful tool that allows glycemic variability quantification and also efficient discrimination between the sustained chronic hyperglycemia and acute glucose fluctuations. The use of CGMS gives potential insights both into overall glycemic control (mean glucose) and variability of such control over the full 24-hour period.
Patients with advanced Chronic Heart Failure (CHF) are inclined to decrease renal capacity due to poor renal perfusion and abundance vasoconstriction. The intense administration of patients with decompensated CHF is frequently muddled by worry for precipitating deteriorating renal capacity. Despite the fact that diuretics and Angiotensin-Converting Enzyme Inhibitors (ACEIs) work on cardiovascular yield and for the most part work on renal perfusion in patients with decompensated CHF, a few patients have deteriorating of renal capacity. When aggravated renal dysfunction does occur, doses of ACEIs and diuretics are often reduced or with held in an attempt to preserve renal function. This training might be improper in patients with diligently raised filling tensions and low cardiovascular yield. Exasperated renal dysfunction may in this way drag out the intense therapy period of CHF, defer the help of indications, and result in imperfect dosing of ACEIs— specialists with portion subordinate long term good results in CHF.
Allen’s therapeutic devices (DATD) that provides Thermobalancing therapy (TT) is a class 1 medical device, so it can be used by everyone at home. 2 thermoelements in DATD accumulate the body heat and become a source of energy. The application of these thermoelements to the back, to the projection of kidneys by DATD dissolves renal calculi gradually. This method for treatment of chronic internal diseases was granted with the US patent as “Therapeutic Device and Method”. It is a fact, confirmed by different clinical investigations that extracorporeal shock wave lithotripsy (ESWL) have serious side effects that can ended with the development of high blood pressure and diabetes. Kidney surgeries, even minimal invasive percutaneous nephrolithotomy (PCNL) can develop severe complication, including secondary hypertension. The only way to dissolve kidney stones without side effects is to use DATD. This new therapy is based on a new understanding of the origin of diseases. According to TT, all chronic internal diseases have the same root, the pathological activity of capillaries. These changes in the small blood vessels, the focus of hypothermia becomes a continuous trigger in the affected tissue, which gradually increases the pressure in the affected organ that leads to its malfunction. The clinical investigations confirmed the effectiveness of TT in 124 men with BPH and 45 men with chronic prostatitis. The collected data during the last decade has shown that TT with DATD has dissolved any type and size of kidney stones in all users. People usually forget about kidney stones within days. However, they should use DATD for several months, depending on the size of renal calculi. Thus, to avoid secondary hypertension and diabetes people with kidney stone disease should use DATD as the first line treatment.